COVID-19 vaccination uptake in people with multiple sclerosis compared to the general population

被引:2
|
作者
Mayer, Dijana [1 ]
Barun, Barbara [2 ,3 ]
Lazibat, Karla [3 ]
Lasic, Slava [3 ]
Adamec, Ivan [2 ,3 ]
Gabelic, Tereza [2 ,3 ]
Skoric, Magdalena Krbot [2 ,4 ]
Habek, Mario [2 ,3 ]
机构
[1] Croatian Inst Publ Hlth, Zagreb, Croatia
[2] Univ Hosp Ctr Zagreb, Referral Ctr Auton Nervous Syst Disorders, Dept Neurol, Kispaticeva 12, Zagreb 10000, Croatia
[3] Univ Zagreb, Sch Med, Zagreb, Croatia
[4] Univ Zagreb, Fac Elect Engn & Comp, Zagreb, Croatia
关键词
Multiple sclerosis; Vaccination; COVID-19;
D O I
10.1007/s13760-023-02296-w
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
ObjectiveTo determine the COVID-19 vaccine uptake among people with multiple sclerosis (pwMS) compared to the general population in Croatia.MethodsData from all pwMS entered in the MS Base register until March 24th, 2022 were extracted including age, sex, MS phenotype, disease-modifying therapy (DMT), and date of COVID-19 vaccination. Data on the general population of Croatia were obtained from the vaccination register of the Croatian Institute of Public Health.Results64.4% pwMS were fully COVID-19 vaccinated which was comparable to 66.3% of the general population. More pwMS were fully vaccinated in the age group 20-24 (74.1% vs 51.7%), and fewer pwMS were fully vaccinated in the age group 65-69 (33.3% vs 80.4%) compared to the general population of the same age group, respectively. PwMS who received at least one dose of any COVID-19 vaccine were older (40.5 vs 37.6 years, p = 0.01), had higher EDSS (2.0 vs 1.0, p = 0.025), and had longer disease duration (6.39 vs 5.35 years, p = 0.02), were more likely to have progressive disease course (p = 0.049) and were on high efficacy DMTs (p = 0.045) compared to unvaccinated pwMS. Longer disease duration positively predicted vaccine uptake.ConclusionCroatia has suboptimal COVID-19 vaccination uptake without a significant difference between the general population and pwMS.
引用
收藏
页码:2269 / 2275
页数:7
相关论文
共 50 条
  • [21] COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis
    Briggs, Farren Basil Shaw
    Mateen, Farrah J.
    Schmidt, Hollie
    Currie, Keisha M.
    Siefers, Heather M.
    Crouthamel, Slavka
    Bebo, Bruce F.
    Fiol, Julie
    Racke, Michael K.
    O'Connor, Kevin C.
    Kolaczkowski, Laura G.
    Klein, Phyllis
    Loud, Sara
    McBurney, Robert Nicholas
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2022, 9 (01):
  • [22] Vaccination and multiple sclerosis in the era of the COVID-19 pandemic
    Monschein, Tobias
    Hartung, Hans-Peter
    Zrzavy, Tobias
    Barnett, Michael
    Boxberger, Nina
    Berger, Thomas
    Chataway, Jeremy
    Bar-Or, Amit
    Rommer, Paulus Stefan
    Zettl, Uwe K.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2021, 92 (10): : 1033 - 1043
  • [23] Impact of vaccination on COVID-19 outcome in multiple sclerosis
    Bsteh, Gabriel
    Gradl, Christiane
    Heschl, Bettina
    Hegen, Harald
    Di Pauli, Franziska
    Assar, Hamid
    Leutmezer, Fritz
    Traxler, Gerhard
    Krajnc, Nik
    Zulehner, Gudrun
    Hiller, Maria-Sophia
    Rommer, Paulus
    Wipfler, Peter
    Guger, Michael
    Enzinger, Christian
    Berger, Thomas
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (11) : 3329 - 3336
  • [24] COVID-19 Vaccine Response in People with Multiple Sclerosis
    Tallantyre, Emma C.
    Vickaryous, Nicola
    Anderson, Valerie
    Asardag, Aliye Nazli
    Baker, David
    Bestwick, Jonathan
    Bramhall, Kath
    Chance, Randy
    Evangelou, Nikos
    George, Katila
    Giovannoni, Gavin
    Godkin, Andrew
    Grant, Leanne
    Harding, Katharine E.
    Hibbert, Aimee
    Ingram, Gillian
    Jones, Meleri
    Kang, Angray S.
    Loveless, Samantha
    Moat, Stuart J.
    Robertson, Neil P.
    Schmierer, Klaus
    Scurr, Martin J.
    Shah, Sita Navin
    Simmons, Jessica
    Upcott, Matthew
    Willis, Mark
    Jolles, Stephen
    Dobson, Ruth
    ANNALS OF NEUROLOGY, 2022, 91 (01) : 89 - 100
  • [25] COVID-19 in people with multiple sclerosis treated with ocrelizumab
    Hauser, S. L.
    Gold, R.
    Cutter, G.
    Fitovski, K.
    Schneble, H. -M.
    Whitley, L.
    Jessop, N.
    Sauter, A.
    Wang, Q.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 762 - 762
  • [26] COVID-19 and multiple sclerosis: a thematic analysis of the unique experiences of people with multiple sclerosis during the COVID-19 pandemic
    Simcock-Davies, A.
    Da Silva, A.
    Craig, E. M.
    Middleton, R. M.
    Nicholas, R.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 686 - 687
  • [27] Safety, immunogenicity, efficacy, and acceptability of COVID-19 vaccination in people with multiple sclerosis: a narrative review
    Capone, Fioravante
    Rossi, Mariagrazia
    Cruciani, Alessandro
    Motolese, Francesco
    Pilato, Fabio
    Di Lazzaro, Vincenzo
    NEURAL REGENERATION RESEARCH, 2023, 18 (02) : 284 - 288
  • [28] COVID-19 humoral and T-cell mediated vaccination responses in people with multiple sclerosis
    Vickaryous, N.
    Rios, F.
    Schalk, L.
    Asardag, A. N.
    George, K.
    Kang, A.
    Baker, D.
    Giovannoni, G.
    Dobson, R.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 680 - 680
  • [29] Safety,immunogenicity,efficacy,and acceptability of COVID-19 vaccination in people with multiple sclerosis:a narrative review
    Fioravante Capone
    Mariagrazia Rossi
    Alessandro Cruciani
    Francesco Motolese
    Fabio Pilato
    Vincenzo Di Lazzaro
    Neural Regeneration Research, 2023, 18 (02) : 284 - 288
  • [30] COVID-19 Experiences and Vaccination in People with Multiple Sclerosis (P1-1.Virtual)
    Brunn, Jenna
    Dunietz, Galit
    Romeo, Andrew
    Braley, Tiffany
    NEUROLOGY, 2022, 98 (18)